Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

5973 - Association of phase angle and chemotherapy toxicity among Mexican patients with non‐metastatic breast cancer

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Supportive Care and Symptom Management

Tumour Site

Breast Cancer

Presenters

Maria Tereza Nieto Coronel

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

M.T. Nieto Coronel1, C.H. Arce- Salinas2, A. Peña-Ruiz2, M.A. Espinoza Cuevas3, J. Santamaria-Galicia2

Author affiliations

  • 1 Medical Oncology, Hospital de Clinicas Universitario, 591 - La Paz/BO
  • 2 Medical Oncology, Instituto Nacional de Cancerologia - Mexico, 14080 - Ciudad de México/MX
  • 3 Nutrition, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubiran, 14080 - Mexico/MX
More

Resources

Abstract 5973

Background

Chemotherapy is the cornerstone of the treatment of patients with non‐metastatic breast cancer; however, its toxicity may be limiting. It has been reported that some degree of toxicity is present in 98% of patients. To date, no predictors of this toxicity have been identified. Bioimpedance and Phase Angle (PA) are non‐invasive procedures to evaluate nutritional status. The aim of this study was to associate the PA with chemotherapy toxicity during (neo)adjuvant (neoCT) treatment of breast cancer.

Methods

172 patients were prospectively evaluated, 31 were excluded because they had metastatic disease or had received endocrine therapy. Only chemotherapy candidates were enrolled, patient selection criteria were PS 0‐1, adequate liver, hematologic and renal function tests. The chemotherapy regimen consisted in AC‐T at standard doses and schedules +/‐ cisplatin in triple-negative tumors. Toxicity was evaluated per NCI CTC v4.0. In all patients bioimpedance by SECA mBCA 514 and Inbody 720 were registered. Statistical analysis was done with SPSS v20.0.

Results

141 were analyzed, median age was 50 years old, 53.2% of them received neoCT and 46.8% adjuvant CT. Regarding comorbid status, 10.6% had diabetes, 14.0% had hypertension, most of the patients were obese or over weight, median BMI was 27.7kg/m2 (13.79‐39.84 kg/m2), median waist circumference was 97.30cm (72‐135 kg/m2), overall metabolic syndrome per ATPIII criteria was found in 34.1% of all patients. 54.3% were diagnosed in early stage (I‐IIb), 24.2% were HER2‐positive, 46.8% were HR‐positive and 29.1% were triple negative. Any grade of toxicity was present in 98.6%, 9.9% required hospitalization and in 2.1% toxicity led to death, most common side effects were gastrointestinal 85.8%, fatigue 70.9%, peripheral neuropathy 50.4% and hematologic 48.9%. PA average was 4.8° (2.8‐6.26°). We found a correlation between PA and any grade of toxicity (p = 0.022). Patients with low PA had more G3-5 toxicity (p = 0.045). and more peripheral neuropathy (p = 0.045).

Conclusions

PA helps us to assess nutritional status and it seems to be useful as a toxicity predictor. However, external validation is necessary to confirm this benefit.

Clinical trial identification

Legal entity responsible for the study

Maria Tereza Nieto Coronel.

Funding

Has not received any funding.

Editorial Acknowledgement

Any

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.